Medtronic reports strong safety and success in cardiac ablation for arrhythmia patients worldwide

Medtronic announced positive real-world results from global registries evaluating its Affera Mapping and Ablation System with Sphere-9 Catheter and PulseSelect Pulsed Field Ablation system. The studies involved over 2,200 patients with atrial fibrillation and ventricular tachycardia, showing low complication rates and high success in arrhythmia treatment. These findings reinforce Medtronic's leadership in cardiac ablation technology and support ongoing innovation to improve patient care globally.

Medtronic PLC (MDT) shares trade at USD 93.25 as of Oct 22, 2026 18:12 WIB, which is closer to its 52-week low of USD 73.75 than its high of USD 105.35. Despite the recent positive clinical results, the stock shows a modest 1-day gain of 0.24% on Pluang, with a high dividend yield of 3.1%. Notably, 93% of Pluang order activity is selling, indicating cautious investor sentiment around this health sector leader.